NeuroSense Therapeutics Ltd.

Cel mai recent trimestru pe care îl avem pentru NeuroSense Therapeutics Ltd.

Din raportul 6-K al companiei.

Ce a spus conducerea

“Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,”

Citat cuvânt cu cuvânt din comunicat și afișat doar atunci când raportarea îl atribuie unei persoane numite.

Cu ce se ocupă NeuroSense Therapeutics Ltd.

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Descrierea proprie a companiei, așa cum apare la finalul comunicatului.